<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7000641/results/search/disease/results.xml">
  <result pre="italic;} Intest ResIntest ResIRIntestinal Research1598-91002288-1956Korean Association for the Study of" exact="Intestinal" post="Diseases pmcid: 7000641 doi: 10.5217/ir.2019.09155ir-2019-09155 : Review Prevention and"/>
  <result pre="Intest ResIntest ResIRIntestinal Research1598-91002288-1956Korean Association for the Study of Intestinal" exact="Diseases" post="pmcid: 7000641 doi: 10.5217/ir.2019.09155ir-2019-09155 : Review Prevention and management"/>
  <result pre="pmcid: 7000641 doi: 10.5217/ir.2019.09155ir-2019-09155 : Review Prevention and management of" exact="viral hepatitis" post="in inflammatory bowel disease: a clinical practice guideline by"/>
  <result pre="7000641 doi: 10.5217/ir.2019.09155ir-2019-09155 : Review Prevention and management of viral" exact="hepatitis" post="in inflammatory bowel disease: a clinical practice guideline by"/>
  <result pre=": Review Prevention and management of viral hepatitis in inflammatory" exact="bowel" post="disease: a clinical practice guideline by the Korean Association"/>
  <result pre="practice guideline by the Korean Association for the Study of" exact="Intestinal" post="Diseases http://orcid.org/0000-0001-8822-9632ParkSoo-Kyung1*http://orcid.org/0000-0001-7089-532XChoiChang Hwan2*http://orcid.org/0000-0002-4212-0380ChunJaeyoung3http://orcid.org/0000-0003-4830-9851LeeHeeyoung4http://orcid.org/0000-0003-1820-459XKimEun Sun5http://orcid.org/0000-0001-9974-1658ParkJae Jun6http://orcid.org/0000-0003-3824-3481ParkChan Hyuk7http://orcid.org/0000-0002-0218-4136LeeBo-In8http://orcid.org/0000-0002-7760-0050JungYunho9http://orcid.org/0000-0003-2307-8575ParkDong-Il1http://orcid.org/0000-0002-8327-3439KimDo Young6http://orcid.org/0000-0001-8449-034XParkHana10http://orcid.org/0000-0003-0220-3816JeenYoon Tae5collab: IBD"/>
  <result pre="guideline by the Korean Association for the Study of Intestinal" exact="Diseases" post="http://orcid.org/0000-0001-8822-9632ParkSoo-Kyung1*http://orcid.org/0000-0001-7089-532XChoiChang Hwan2*http://orcid.org/0000-0002-4212-0380ChunJaeyoung3http://orcid.org/0000-0003-4830-9851LeeHeeyoung4http://orcid.org/0000-0003-1820-459XKimEun Sun5http://orcid.org/0000-0001-9974-1658ParkJae Jun6http://orcid.org/0000-0003-3824-3481ParkChan Hyuk7http://orcid.org/0000-0002-0218-4136LeeBo-In8http://orcid.org/0000-0002-7760-0050JungYunho9http://orcid.org/0000-0003-2307-8575ParkDong-Il1http://orcid.org/0000-0002-8327-3439KimDo Young6http://orcid.org/0000-0001-8449-034XParkHana10http://orcid.org/0000-0003-0220-3816JeenYoon Tae5collab: IBD Research"/>
  <result pre="Research Group of the Korean Association for the Study of" exact="Intestinal" post="Diseases[1], Korea[2], Korea[3], Korea[4], Korea[5], Korea[6], Korea[7], Korea[8], Korea[9],"/>
  <result pre="the original work is properly cited. Abstract The treatment of" exact="inflammatory bowel disease" post="(IBD) has been revolutionized for the last 10 years"/>
  <result pre="original work is properly cited. Abstract The treatment of inflammatory" exact="bowel" post="disease (IBD) has been revolutionized for the last 10"/>
  <result pre="work is properly cited. Abstract The treatment of inflammatory bowel" exact="disease" post="(IBD) has been revolutionized for the last 10 years"/>
  <result pre="of immunomodulators and biologics. With immunosuppression of this kind, opportunistic" exact="infection" post="is an important safety concern for patients with IBD."/>
  <result pre="an important safety concern for patients with IBD. In particular," exact="viral hepatitis" post="is determined by the interaction between the virus and"/>
  <result pre="important safety concern for patients with IBD. In particular, viral" exact="hepatitis" post="is determined by the interaction between the virus and"/>
  <result pre="by immunosuppression therapy. Parts of Asia, including Korea, still show" exact="intermediate" post="endemicity for the hepatitis A virus and hepatitis B"/>
  <result pre="of Asia, including Korea, still show intermediate endemicity for the" exact="hepatitis" post="A virus and hepatitis B virus compared with the"/>
  <result pre="still show intermediate endemicity for the hepatitis A virus and" exact="hepatitis" post="B virus compared with the United States and Western"/>
  <result pre="research group of the Korean Association for the Study of" exact="Intestinal" post="Diseases have produced a guideline on the prevention and"/>
  <result pre="group of the Korean Association for the Study of Intestinal" exact="Diseases" post="have produced a guideline on the prevention and management"/>
  <result pre="have produced a guideline on the prevention and management of" exact="viral hepatitis" post="in IBD. Inflammatory bowel disease Viral hepatitis Vaccination Prevention"/>
  <result pre="produced a guideline on the prevention and management of viral" exact="hepatitis" post="in IBD. Inflammatory bowel disease Viral hepatitis Vaccination Prevention"/>
  <result pre="on the prevention and management of viral hepatitis in IBD." exact="Inflammatory" post="bowel disease Viral hepatitis Vaccination Prevention INTRODUCTION The treatment"/>
  <result pre="the prevention and management of viral hepatitis in IBD. Inflammatory" exact="bowel" post="disease Viral hepatitis Vaccination Prevention INTRODUCTION The treatment of"/>
  <result pre="prevention and management of viral hepatitis in IBD. Inflammatory bowel" exact="disease" post="Viral hepatitis Vaccination Prevention INTRODUCTION The treatment of IBD"/>
  <result pre="and management of viral hepatitis in IBD. Inflammatory bowel disease" exact="Viral hepatitis" post="Vaccination Prevention INTRODUCTION The treatment of IBD has been"/>
  <result pre="management of viral hepatitis in IBD. Inflammatory bowel disease Viral" exact="hepatitis" post="Vaccination Prevention INTRODUCTION The treatment of IBD has been"/>
  <result pre="of immunomodulators and biologics. With immunosuppression of this kind, opportunistic" exact="infection" post="becomes a key safety concern in patients with IBD"/>
  <result pre="in patients with IBD [1]. In particular, the course of" exact="viral hepatitis" post="is determined by the interaction between the virus and"/>
  <result pre="patients with IBD [1]. In particular, the course of viral" exact="hepatitis" post="is determined by the interaction between the virus and"/>
  <result pre="a considerable proportion of cases [2,3]. Thus, risk assessment for" exact="viral hepatitis" post="is one of the important quality process indicators for"/>
  <result pre="considerable proportion of cases [2,3]. Thus, risk assessment for viral" exact="hepatitis" post="is one of the important quality process indicators for"/>
  <result pre="[4]. In addition, several areas of Asia, including Korea, show" exact="intermediate" post="endemicity for the HAV, while HBV shows moderate prevalence"/>
  <result pre="research group of the Korean Association for the Study of" exact="Intestinal" post="Diseases (KASID) provide a consensus on the prevention and"/>
  <result pre="group of the Korean Association for the Study of Intestinal" exact="Diseases" post="(KASID) provide a consensus on the prevention and management"/>
  <result pre="(KASID) provide a consensus on the prevention and management of" exact="viral hepatitis" post="in IBD. METHODS 1. Direction The IBD Research Group"/>
  <result pre="provide a consensus on the prevention and management of viral" exact="hepatitis" post="in IBD. METHODS 1. Direction The IBD Research Group"/>
  <result pre="produce a evidence-based guideline on the prevention and management of" exact="viral hepatitis" post="in patients with IBD in April 2018. To establish"/>
  <result pre="a evidence-based guideline on the prevention and management of viral" exact="hepatitis" post="in patients with IBD in April 2018. To establish"/>
  <result pre="April 2, 2018. The guidelines addressed prevention and management of" exact="viral hepatitis" post="in patients with IBD. We focused on prevention and"/>
  <result pre="2, 2018. The guidelines addressed prevention and management of viral" exact="hepatitis" post="in patients with IBD. We focused on prevention and"/>
  <result pre="IBD. We focused on prevention and monitoring, and treatment of" exact="viral hepatitis" post="are not included in this guideline. The guidelines were"/>
  <result pre="We focused on prevention and monitoring, and treatment of viral" exact="hepatitis" post="are not included in this guideline. The guidelines were"/>
  <result pre="foreign and Korean guidelines on the prevention and management of" exact="viral hepatitis" post="in IBD. However, in the case of 3 key"/>
  <result pre="and Korean guidelines on the prevention and management of viral" exact="hepatitis" post="in IBD. However, in the case of 3 key"/>
  <result pre="2015 Korean Association for the Study of the Liver (KASL)" exact="hepatitis" post="B guidelines were updated as the 2018 KASL hepatitis"/>
  <result pre="(KASL) hepatitis B guidelines were updated as the 2018 KASL" exact="hepatitis" post="B guidelines, and we adapted the updated guideline. Finally,"/>
  <result pre="of the evidence-based guideline on the prevention and management of" exact="viral hepatitis" post="in IBD was presented and proceeded with primary online"/>
  <result pre="the evidence-based guideline on the prevention and management of viral" exact="hepatitis" post="in IBD was presented and proceeded with primary online"/>
  <result pre="of viral hepatitis in IBD was presented and proceeded with" exact="primary" post="online voting by 40 national IBD specialists who are"/>
  <result pre="by the KASL. The final draft will be published by" exact="Intestinal" post="Research and will be provided by the Korean Medical"/>
  <result pre="and newly presented evidence on the prevention and management of" exact="viral hepatitis" post="in patients with IBD. HEPATITIS A VIRUS 1. Epidemiology"/>
  <result pre="newly presented evidence on the prevention and management of viral" exact="hepatitis" post="in patients with IBD. HEPATITIS A VIRUS 1. Epidemiology"/>
  <result pre="by poor hygiene, and contaminated food or drink [17,18]. HAV" exact="infection" post="is usually a self-limiting illness that does not become"/>
  <result pre="that does not become chronic, unlike HBV or HCV. Instead," exact="infection" post="confers lifelong immunity and is preventable via vaccination. Furthermore,"/>
  <result pre="and is preventable via vaccination. Furthermore, HAV rarely develops into" exact="acute" post="fulminant hepatitis, which can cause death. HAV infection is"/>
  <result pre="develops into acute fulminant hepatitis, which can cause death. HAV" exact="infection" post="is prevalent around the world, but it shows various"/>
  <result pre="used as most adults acquire natural immunity. In areas of" exact="intermediate" post="endemicity (such as Central and South America, Eastern Europe,"/>
  <result pre="acquire natural immunity. In areas of intermediate endemicity (such as" exact="Central" post="and South America, Eastern Europe, and parts of Asia),"/>
  <result pre="Central and South America, Eastern Europe, and parts of Asia)," exact="childhood" post="transmission is less frequent, while adolescents and adults are"/>
  <result pre="more frequently infected, and outbreaks are common. These countries with" exact="intermediate" post="endemicity would benefit most from universal immunization of children."/>
  <result pre="low endemicity (such as the United States and Western Europe)," exact="infection" post="is less frequent, but the disease does occur among"/>
  <result pre="States and Western Europe), infection is less frequent, but the" exact="disease" post="does occur among people in high-risk groups and as"/>
  <result pre="uncertain 0%, disagree 0%, strongly disagree 0% Most cases of" exact="hepatitis" post="A are directly transmitted through the fecal-oral route, but"/>
  <result pre="water, blood, or sexual activity. Thus, the Korea Centers for" exact="Disease" post="Control and Prevention and the Advisory Committee on Immunization"/>
  <result pre="Committee on Immunization Practices of the United States Centers for" exact="Disease" post="Control and Prevention, recommend protection (ideally vaccination) prior to"/>
  <result pre="Control and Prevention, recommend protection (ideally vaccination) prior to potential" exact="hepatitis" post="A exposure in the following high-risk groups [21,22]: those"/>
  <result pre="those traveling to or working in countries with high or" exact="intermediate" post="endemicity of HAV, men who engage in sexual activity"/>
  <result pre="primates or with HAV in a research laboratory, those with" exact="chronic" post="liver disease, those with clotting factor disorders, and those"/>
  <result pre="or with HAV in a research laboratory, those with chronic" exact="liver disease," post="those with clotting factor disorders, and those in direct"/>
  <result pre="disorders, and those in direct contact with others who have" exact="hepatitis" post="A. Patients with IBD are not included in this"/>
  <result pre="not included in this high-risk group, and their potential for" exact="hepatitis" post="A exposure might not different from those without IBD."/>
  <result pre="recommended in immunocompromised patients, as well as in those with" exact="chronic" post="liver disease [21]. In HAV, IgG antibodies appear early"/>
  <result pre="in immunocompromised patients, as well as in those with chronic" exact="liver disease" post="[21]. In HAV, IgG antibodies appear early in the"/>
  <result pre="immunocompromised patients, as well as in those with chronic liver" exact="disease" post="[21]. In HAV, IgG antibodies appear early in the"/>
  <result pre="disease [21]. In HAV, IgG antibodies appear early in the" exact="infection" post="phase and remain throughout the patient’s life, preventing disease."/>
  <result pre="economic development in Korea, a rapid epidemiological shift in HAV" exact="infection" post="has occurred [20,23]. Most adults had immunity to HAV"/>
  <result pre="occurred [20,23]. Most adults had immunity to HAV because of" exact="childhood" post="exposure in 1980, but people in their teens or"/>
  <result pre="of anti-HAV IgG in 2010 [23]. Thus, the number of" exact="adult" post="infected with acute hepatitis A has increased rapidly over"/>
  <result pre="in 2010 [23]. Thus, the number of adult infected with" exact="acute hepatitis" post="A has increased rapidly over the past decade. Since"/>
  <result pre="2010 [23]. Thus, the number of adult infected with acute" exact="hepatitis" post="A has increased rapidly over the past decade. Since"/>
  <result pre="35%, agree 55%, uncertain 7.5%, disagree 0%, strongly disagree 2.5%" exact="Hepatitis" post="A is preventable by vaccination. Currently, inactivated HAV vaccines"/>
  <result pre="dose plus booster dose). Since 1992, 4 interchangeable inactivated monovalent" exact="hepatitis" post="A vaccines have become, available which provided protection against"/>
  <result pre="least 20–25 years after vaccination [25]. Although a live, attenuated" exact="hepatitis" post="A vaccine is used in some areas because it"/>
  <result pre="can be highly immunogenic for up to 11 years after" exact="primary" post="vaccination [27]. Hepatitis A vaccines are safe and highly"/>
  <result pre="immunogenic for up to 11 years after primary vaccination [27]." exact="Hepatitis" post="A vaccines are safe and highly immunogenic in healthy"/>
  <result pre="patients [28-30]. Regarding antibody response according to the number of" exact="hepatitis" post="A vaccinations, several studies involving patients with various diseases"/>
  <result pre="2 vaccinations than after one vaccination [27,31-33]. Immunosuppressive therapy can" exact="lower" post="the antibody response rate of a vaccination. One study"/>
  <result pre="The overall seroconversion rate was 97.6%, but it was significantly" exact="lower" post="in patients treated with the antiTNF monoclonal antibody than"/>
  <result pre="99.1%, respectively; P= 0.001). Furthermore, the seroconversion rate was significantly" exact="lower" post="in patients treated with ≥ 2 than with, &amp;lt;"/>
  <result pre="transmitted through ingestion of contaminated food or drink and causes" exact="acute hepatitis" post="[35]. Soon after IBD diagnosis, clinicians should check hepatitis"/>
  <result pre="through ingestion of contaminated food or drink and causes acute" exact="hepatitis" post="[35]. Soon after IBD diagnosis, clinicians should check hepatitis"/>
  <result pre="acute hepatitis [35]. Soon after IBD diagnosis, clinicians should check" exact="hepatitis" post="A vaccination history for patients, evaluate their protective antibody"/>
  <result pre="in such patients could be considered 4–6 weeks after a" exact="primary" post="course of vaccinations [15]. There are no data on"/>
  <result pre="vaccination. HEPATITIS B VIRUS 1. Epidemiology The HBV is an" exact="infectious disease," post="with 248 million carriers globally. About 600,000 people die"/>
  <result pre="248 million carriers globally. About 600,000 people die of HBV-related" exact="liver disease" post="annually [36]. Although effective vaccination programs are underway, and"/>
  <result pre="million carriers globally. About 600,000 people die of HBV-related liver" exact="disease" post="annually [36]. Although effective vaccination programs are underway, and"/>
  <result pre="vaccination programs are underway, and the rate of new HBV" exact="infections" post="has been significantly reduced, HBV is still a major"/>
  <result pre="of morbidity and mortality. HBV can be clinically classified as" exact="acute" post="and chronic. In the acute phase, the virus may"/>
  <result pre="can be clinically classified as acute and chronic. In the" exact="acute" post="phase, the virus may manifest as subacute, non-icteric hepatitis,"/>
  <result pre="subacute, non-icteric hepatitis, icteric hepatitis, and sometimes fulminant hepatitis. The" exact="chronic" post="phase can be an asymptomatic carrier phase, but it"/>
  <result pre="an asymptomatic carrier phase, but it may also manifest as" exact="chronic hepatitis," post="liver cirrhosis, or hepatocellular carcinoma. Both acute and chronic"/>
  <result pre="carrier phase, but it may also manifest as chronic hepatitis," exact="liver cirrhosis," post="or hepatocellular carcinoma. Both acute and chronic HBV infection"/>
  <result pre="it may also manifest as chronic hepatitis, liver cirrhosis, or" exact="hepatocellular carcinoma." post="Both acute and chronic HBV infection may be accompanied"/>
  <result pre="manifest as chronic hepatitis, liver cirrhosis, or hepatocellular carcinoma. Both" exact="acute" post="and chronic HBV infection may be accompanied by extrahepatic"/>
  <result pre="chronic hepatitis, liver cirrhosis, or hepatocellular carcinoma. Both acute and" exact="chronic" post="HBV infection may be accompanied by extrahepatic symptoms. The"/>
  <result pre="liver cirrhosis, or hepatocellular carcinoma. Both acute and chronic HBV" exact="infection" post="may be accompanied by extrahepatic symptoms. The prevalence of"/>
  <result pre="etc.), 2%–7% in those with moderate prevalence (e.g., South Korea," exact="Mediterranean" post="countries, Japan, Central Asia, Middle East, and parts of"/>
  <result pre="those with moderate prevalence (e.g., South Korea, Mediterranean countries, Japan," exact="Central" post="Asia, Middle East, and parts of South America), and"/>
  <result pre="no longer an endemic area, but is classified as having" exact="intermediate" post="endemicity [39,40]. In the 1980s, HBsAg-positive carriers comprised 8%–10%"/>
  <result pre="and 0.3% in 2016. In IBD patients, the prevalence of" exact="chronic" post="HBV infection (positive HBsAg, positive anti-HBc, and negative anti-HBs)"/>
  <result pre="in 2016. In IBD patients, the prevalence of chronic HBV" exact="infection" post="(positive HBsAg, positive anti-HBc, and negative anti-HBs) was 3.8%"/>
  <result pre="HBsAg, positive anti-HBc, and negative anti-HBs) was 3.8% and past" exact="infection" post="(negative HBsAg, positive anti-HBc, and positive or negative anti-HBs)"/>
  <result pre="World Health Organization (WHO) has estimated that the prevalence of" exact="chronic hepatitis" post="B infection in children under 5 years will be"/>
  <result pre="Health Organization (WHO) has estimated that the prevalence of chronic" exact="hepatitis" post="B infection in children under 5 years will be"/>
  <result pre="(WHO) has estimated that the prevalence of chronic hepatitis B" exact="infection" post="in children under 5 years will be 1% in"/>
  <result pre="Therefore, all patients with IBD should be assessed for HBV" exact="infection" post="(HBsAg, anti-HBs, anti-HBc) or immunization status. Patients who are"/>
  <result pre="of HBV reactivation during biologic treatments for patients with a" exact="rheumatic" post="disease was 12.3% in HBsAg-positive plus anti-HBc positive patients"/>
  <result pre="HBV reactivation during biologic treatments for patients with a rheumatic" exact="disease" post="was 12.3% in HBsAg-positive plus anti-HBc positive patients [46],"/>
  <result pre="reactivation. However, anti-HBs testing may be helpful for detecting past" exact="infection" post="in patients who are HBsAg-negative and anti-HBc-positive. Furthermore, loss"/>
  <result pre="administering the HBV vaccine after birth—in all countries with high," exact="intermediate" post="and low endemicity [56]. Despite these recommendations, the rate"/>
  <result pre="12% of patients were administered HBV vaccine [53]. Since HBV" exact="infection" post="is relatively common in Korea, specific attention should be"/>
  <result pre="isolated anti-HBc positive cases in areas with high prevalence of" exact="hepatitis" post="B, such as Korea, is past HBV infection, where"/>
  <result pre="diagnosis, immunosuppressive therapy is commenced, where possible, especially because the" exact="disease" post="follows an unpredictable course and necessitates immunosuppressive therapy [5,12]."/>
  <result pre="administered with commencement of immunosuppressive drugs. The standard course of" exact="hepatitis" post="B vaccination consists of 3 doses administered at 0,"/>
  <result pre="patients, 41% of those receiving standard cycle of the commercial" exact="hepatitis" post="B vaccine at 0, 1, and 6 months attained"/>
  <result pre="developed after several weeks. This was observed in patients with" exact="rheumatoid arthritis," post="but patients with ankylosing spondylitis revealed good antibody responses,"/>
  <result pre="was observed in patients with rheumatoid arthritis, but patients with" exact="ankylosing spondylitis" post="revealed good antibody responses, regardless of the time of"/>
  <result pre="observed in patients with rheumatoid arthritis, but patients with ankylosing" exact="spondylitis" post="revealed good antibody responses, regardless of the time of"/>
  <result pre="immunomodulator and anti-TNF agent, the immune response to vaccines is" exact="lower" post="than in those on monotherapy with an immunomodulator, anti-TNF,"/>
  <result pre="administered HBV vaccine, but did reduce the response to oral" exact="cholera" post="vaccine [70]. In healthy individuals, routine immunity testing after"/>
  <result pre="some debate about what titer level represents adequate protection against" exact="hepatitis" post="B, with some groups recommending titers of anti-HBs above"/>
  <result pre="IU/L [61,72]. According to recently published clinical practice guidelines for" exact="hepatitis" post="B in Korea, the level of protective titer of"/>
  <result pre="1 to 2 months after completion of vaccinations [73]. Although" exact="primary" post="hepatitis B vaccination series is completed and HBV seroprotection"/>
  <result pre="to 2 months after completion of vaccinations [73]. Although primary" exact="hepatitis" post="B vaccination series is completed and HBV seroprotection is"/>
  <result pre="receiving immunosuppressive therapy, even if HBV seroprotection is achieved after" exact="complete" post="vaccination. Based on expert opinion, anti-HBs should be monitored"/>
  <result pre="the vaccine booster dose is better preserved than that to" exact="primary" post="vaccination, because more memory T and B cells are"/>
  <result pre="therapy usually generates protective titers, but antibody responses may be" exact="lower" post="than in those without immunosuppressive therapy. A booster dose"/>
  <result pre="Prophylaxis Statement 7 HBsAg-positive and/or HBV DNA-positive (i.e., those with" exact="chronic" post="HBV infection) IBD patients who require moderateto-high risk immunosuppressive"/>
  <result pre="reactivation is defined as active inflammation occurring after inactivity in" exact="chronic hepatitis" post="B or after resolution of a past HBV infection."/>
  <result pre="is defined as active inflammation occurring after inactivity in chronic" exact="hepatitis" post="B or after resolution of a past HBV infection."/>
  <result pre="infection. HBV reactivation is classified as follows: (1) exacerbation of" exact="chronic" post="HBV infection in patients who are HBsAg-positive, or (2)"/>
  <result pre="reactivation is classified as follows: (1) exacerbation of chronic HBV" exact="infection" post="in patients who are HBsAg-positive, or (2) relapse of"/>
  <result pre="patients who are HBsAg-positive, or (2) relapse of past HBV" exact="infection" post="in patients who are HBsAg-negative plus anti-HBc-positive [80]. Exacerbation"/>
  <result pre="in patients who are HBsAg-negative plus anti-HBc-positive [80]. Exacerbation of" exact="chronic" post="HBV infection is defined as a more than a"/>
  <result pre="who are HBsAg-negative plus anti-HBc-positive [80]. Exacerbation of chronic HBV" exact="infection" post="is defined as a more than a 100-fold rise"/>
  <result pre="among patients who are HBsAg-positive [3]. Relapse of past HBV" exact="infection" post="is detected based on reverse seroconversion (seroreversion) from HBsAg-negativity"/>
  <result pre="HBsAg-negative plus anti-HBc-positive [3]. In patients with HBV reactivation, a" exact="hepatitis" post="flare-up can occur, which is evidenced demonstrated by a"/>
  <result pre="more than 50% of patients who experienced HBV reactivation had" exact="liver failure" post="[45,97]. Importantly, most cases of HBV reactivation developed in"/>
  <result pre="antiHBc-positive is HBsAg reappearance (seroreversion), which is closely associated with" exact="hepatitis" post="flare [106]. Therefore, pre-emptive therapy is based upon monitoring"/>
  <result pre="discontinued [113-117]. Patients who are HBsAg-negative plus anti-HBc-positive are at" exact="lower" post="risk of HBV reactivation than those who are HBsAgpositive."/>
  <result pre="these patients [118], and HBsAg seroreversion is constantly associated with" exact="hepatitis" post="flare-ups, even though HBV DNA detection leads to seroreversion"/>
  <result pre="flare-ups, even though HBV DNA detection leads to seroreversion and" exact="hepatitis" post="in only 50% of cases [106]. These patients should"/>
  <result pre="≥ 70 years, respectively [121]. A high-risk group for HCV" exact="infection" post="includes individuals who inject drugs, patients who undergo dialysis,"/>
  <result pre="individuals who inject drugs, patients who undergo dialysis, those with" exact="hemophilia" post="or Hansen’s disease, and children born to HCV-positive mothers"/>
  <result pre="positive, HCV RNA titer should be checked to confirm HCV" exact="infection" post="(strong for recommendation, moderate level of evidence). · Level"/>
  <result pre="0% Thanks to recent advancements in medication for HCV, most" exact="infections" post="can be cured. In fact, HCV elimination is now"/>
  <result pre="patients’ HCV RNA titer should be tested to confirm HCV" exact="infection" post="[126]. If infection is confirmed, patients should be treated"/>
  <result pre="titer should be tested to confirm HCV infection [126]. If" exact="infection" post="is confirmed, patients should be treated according to the"/>
  <result pre="to the HCV clinical practice guidelines [7]. If possible, HCV" exact="infection" post="should be treated before biologic treatments of IBD are"/>
  <result pre="be monitored closely. In a previous systematic review involving a" exact="total" post="of 153 patients with HCV who had been treated"/>
  <result pre="HCV who had been treated using TNF-α inhibitor, mainly for" exact="rheumatoid arthritis," post="worsening HCV infection was identified in only one patient"/>
  <result pre="treated using TNF-α inhibitor, mainly for rheumatoid arthritis, worsening HCV" exact="infection" post="was identified in only one patient [124]. The benefits"/>
  <result pre="of immunosuppressive therapy in patients with IBD who have active" exact="disease" post="status likely outweigh the risks of the therapy. However,"/>
  <result pre="reduce drug efficacy [7]. CONCLUSION In patients with IBD, opportunistic" exact="infection" post="is a key safety concern with the increasing use"/>
  <result pre="patients with IBD. As Korea is still an area of" exact="intermediate" post="HAV and HBV endemicity, we hope that these guidelines"/>
  <result pre="hope that these guidelines for the prevention and management of" exact="viral hepatitis" post="in IBD will prevent hepatitis viral infection and reactivation,"/>
  <result pre="that these guidelines for the prevention and management of viral" exact="hepatitis" post="in IBD will prevent hepatitis viral infection and reactivation,"/>
  <result pre="prevention and management of viral hepatitis in IBD will prevent" exact="hepatitis" post="viral infection and reactivation, and that it will lessen"/>
  <result pre="and management of viral hepatitis in IBD will prevent hepatitis" exact="viral infection" post="and reactivation, and that it will lessen confusion among"/>
  <result pre="management of viral hepatitis in IBD will prevent hepatitis viral" exact="infection" post="and reactivation, and that it will lessen confusion among"/>
  <result pre="REFERENCES 1OoiCJHilmiIBanerjeeRet al.Best practices on immunomodulators and biologic agents for" exact="ulcerative colitis" post="and Crohn’s disease in AsiaIntest Res20191728531031146509 2RahierJFMagroFAbreuCet al.Second European"/>
  <result pre="1OoiCJHilmiIBanerjeeRet al.Best practices on immunomodulators and biologic agents for ulcerative" exact="colitis" post="and Crohn’s disease in AsiaIntest Res20191728531031146509 2RahierJFMagroFAbreuCet al.Second European"/>
  <result pre="on immunomodulators and biologic agents for ulcerative colitis and Crohn’s" exact="disease" post="in AsiaIntest Res20191728531031146509 2RahierJFMagroFAbreuCet al.Second European evidencebased consensus on"/>
  <result pre="evidencebased consensus on the prevention, diagnosis and management of opportunistic" exact="infections" post="in inflammatory bowel diseaseJ Crohns Colitis2014844346824613021 3collab: Korean Association"/>
  <result pre="the prevention, diagnosis and management of opportunistic infections in inflammatory" exact="bowel" post="diseaseJ Crohns Colitis2014844346824613021 3collab: Korean Association for the Study"/>
  <result pre="the Study of the LiverKASL clinical practice guidelines: management of" exact="chronic hepatitis" post="BClin Mol Hepatol201622187527044762 4YeBDTravisSImproving the quality of care for"/>
  <result pre="Study of the LiverKASL clinical practice guidelines: management of chronic" exact="hepatitis" post="BClin Mol Hepatol201622187527044762 4YeBDTravisSImproving the quality of care for"/>
  <result pre="BClin Mol Hepatol201622187527044762 4YeBDTravisSImproving the quality of care for inflammatory" exact="bowel" post="diseaseIntest Res201917455330449081 5FarrayeFAMelmedGYLichtensteinGRKaneSVACG clinical guideline: preventive care in inflammatory"/>
  <result pre="bowel diseaseIntest Res201917455330449081 5FarrayeFAMelmedGYLichtensteinGRKaneSVACG clinical guideline: preventive care in inflammatory" exact="bowel" post="diseaseAm J Gastroenterol201711224125828071656 6collab: European Association for the Study"/>
  <result pre="the LiverEASL 2017 clinical practice guidelines on the management of" exact="hepatitis" post="B virus infectionJ Hepatol20176737039828427875 7collab: European Association for the"/>
  <result pre="for the Study of the LiverEASL recommendations on treatment of" exact="hepatitis" post="C 2018J Hepatol20186946151129650333 8TerraultNALokASFMcMahonBJet al.Update on prevention, diagnosis, and"/>
  <result pre="2018J Hepatol20186946151129650333 8TerraultNALokASFMcMahonBJet al.Update on prevention, diagnosis, and treatment of" exact="chronic hepatitis" post="B: AASLD 2018 hepatitis B guidanceHepatology2018671560159929405329 9collab: Korean Association"/>
  <result pre="Hepatol20186946151129650333 8TerraultNALokASFMcMahonBJet al.Update on prevention, diagnosis, and treatment of chronic" exact="hepatitis" post="B: AASLD 2018 hepatitis B guidanceHepatology2018671560159929405329 9collab: Korean Association"/>
  <result pre="prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018" exact="hepatitis" post="B guidanceHepatology2018671560159929405329 9collab: Korean Association for the Study of"/>
  <result pre="of the Liver (KASL)2017 KASL clinical practice guidelines management of" exact="hepatitis" post="C: treatment of chronic hepatitis CClin Mol Hepatol20182416922930092624 10collab:"/>
  <result pre="KASL clinical practice guidelines management of hepatitis C: treatment of" exact="chronic hepatitis" post="CClin Mol Hepatol20182416922930092624 10collab: Korean Association for the Study"/>
  <result pre="clinical practice guidelines management of hepatitis C: treatment of chronic" exact="hepatitis" post="CClin Mol Hepatol20182416922930092624 10collab: Korean Association for the Study"/>
  <result pre="of the Liver (KASL)KASL clinical practice guidelines for management of" exact="chronic hepatitis" post="BClin Mol Hepatol2019259315931185710 11SinghJASaagKGBridgesSLJret al.2015 American College of Rheumatology"/>
  <result pre="the Liver (KASL)KASL clinical practice guidelines for management of chronic" exact="hepatitis" post="BClin Mol Hepatol2019259315931185710 11SinghJASaagKGBridgesSLJret al.2015 American College of Rheumatology"/>
  <result pre="for management of chronic hepatitis BClin Mol Hepatol2019259315931185710 11SinghJASaagKGBridgesSLJret al.2015" exact="American" post="College of Rheumatology Guideline for the treatment of rheumatoid"/>
  <result pre="13BombardierCHazlewoodGSAkhavanPet al.Canadian Rheumatology Association recommendations for the pharmacological management of" exact="rheumatoid arthritis" post="with traditional and biologic disease-modifying antirheumatic drugs: part II"/>
  <result pre="al.Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid" exact="arthritis" post="with traditional and biologic disease-modifying antirheumatic drugs: part II"/>
  <result pre="II safetyJ Rheumatol2012391583160222707613 14van AssenSAgmon-LevinNElkayamOet al.EULAR recommendations for vaccination in" exact="adult" post="patients with autoimmune inflammatory rheumatic diseasesAnn Rheum Dis20117041442221131643 15BühlerSEperonGRibiCet"/>
  <result pre="14van AssenSAgmon-LevinNElkayamOet al.EULAR recommendations for vaccination in adult patients with" exact="autoimmune" post="inflammatory rheumatic diseasesAnn Rheum Dis20117041442221131643 15BühlerSEperonGRibiCet al.Vaccination recommendations for"/>
  <result pre="al.EULAR recommendations for vaccination in adult patients with autoimmune inflammatory" exact="rheumatic" post="diseasesAnn Rheum Dis20117041442221131643 15BühlerSEperonGRibiCet al.Vaccination recommendations for adult patients"/>
  <result pre="autoimmune inflammatory rheumatic diseasesAnn Rheum Dis20117041442221131643 15BühlerSEperonGRibiCet al.Vaccination recommendations for" exact="adult" post="patients with autoimmune inflammatory rheumatic diseasesSwiss Med Wkly2015145w1415926218860 16CordeiroIDuarteACFerreiraJFet"/>
  <result pre="diseasesAnn Rheum Dis20117041442221131643 15BühlerSEperonGRibiCet al.Vaccination recommendations for adult patients with" exact="autoimmune" post="inflammatory rheumatic diseasesSwiss Med Wkly2015145w1415926218860 16CordeiroIDuarteACFerreiraJFet al.Recommendations for vaccination"/>
  <result pre="Dis20117041442221131643 15BühlerSEperonGRibiCet al.Vaccination recommendations for adult patients with autoimmune inflammatory" exact="rheumatic" post="diseasesSwiss Med Wkly2015145w1415926218860 16CordeiroIDuarteACFerreiraJFet al.Recommendations for vaccination in adult"/>
  <result pre="inflammatory rheumatic diseasesSwiss Med Wkly2015145w1415926218860 16CordeiroIDuarteACFerreiraJFet al.Recommendations for vaccination in" exact="adult" post="patients with systemic inflammatory rheumatic diseases from the Portuguese"/>
  <result pre="Med Wkly2015145w1415926218860 16CordeiroIDuarteACFerreiraJFet al.Recommendations for vaccination in adult patients with" exact="systemic" post="inflammatory rheumatic diseases from the Portuguese Society of RheumatologyActa"/>
  <result pre="16CordeiroIDuarteACFerreiraJFet al.Recommendations for vaccination in adult patients with systemic inflammatory" exact="rheumatic" post="diseases from the Portuguese Society of RheumatologyActa Reumatol Port20164111213027606471"/>
  <result pre="17CuthbertJAHepatitis A: old and newClin Microbiol Rev200114385811148002 18HussainZDasBCHusainSAMurthyNSKarPIncreasing trend of" exact="acute hepatitis" post="A in north India: need for identification of high-risk"/>
  <result pre="A: old and newClin Microbiol Rev200114385811148002 18HussainZDasBCHusainSAMurthyNSKarPIncreasing trend of acute" exact="hepatitis" post="A in north India: need for identification of high-risk"/>
  <result pre="population for vaccinationJ Gastroenterol Hepatol20062168969316677154 19BellBPShapiroCNAlterMJet al.The diverse patterns of" exact="hepatitis" post="A epidemiology in the United States: implications for vaccination"/>
  <result pre="for vaccination strategiesJ Infect Dis1998178157915849815207 20MoonHWChoJHHurMet al.Laboratory characteristics of recent" exact="hepatitis" post="A in Korea: ongoing epidemiological shiftWorld J Gastroenterol2010161115111820205283 21NelsonNPLink-GellesRHofmeisterMGet"/>
  <result pre="of the advisory committee on immunization practices for use of" exact="hepatitis" post="A vaccine for postexposure prophylaxis and for preexposure prophylaxis"/>
  <result pre="international travelMMWR Morb Mortal Wkly Rep2018671216122030383742 22collab: Korea Centers for" exact="Disease" post="Control (KCDC)Epidemiology and management of vaccine preventable disease5th edCheongjuKCDC2017"/>
  <result pre="al.Hepatitis A booster vaccination: is there a need?Lancet20033621065107114522539 26XuZYWangXYLive attenuated" exact="hepatitis" post="A vaccines developed in ChinaHum Vaccin Immunother20141065966624280971 27OttJJWiersmaSTSingle-dose administration"/>
  <result pre="vaccines developed in ChinaHum Vaccin Immunother20141065966624280971 27OttJJWiersmaSTSingle-dose administration of inactivated" exact="hepatitis" post="A vaccination in the context of hepatitis A vaccine"/>
  <result pre="administration of inactivated hepatitis A vaccination in the context of" exact="hepatitis" post="A vaccine recommendationsInt J Infect Dis201317e939e94423791857 28InnisBLSnitbhanRKunasolPet al.Protection against"/>
  <result pre="hepatitis A vaccine recommendationsInt J Infect Dis201317e939e94423791857 28InnisBLSnitbhanRKunasolPet al.Protection against" exact="hepatitis" post="A by an inactivated vaccineJAMA1994271132813348158817 29IrvingGJHoldenJYangRPopeDHepatitis A immunisation in"/>
  <result pre="vaccineJAMA1994271132813348158817 29IrvingGJHoldenJYangRPopeDHepatitis A immunisation in persons not previously exposed to" exact="hepatitis" post="ACochrane Database Syst Rev20127CD00905122786522 30RiedemannSReinhardtGFrösnerGGet al.Placebo-controlled efficacy study of"/>
  <result pre="hepatitis ACochrane Database Syst Rev20127CD00905122786522 30RiedemannSReinhardtGFrösnerGGet al.Placebo-controlled efficacy study of" exact="hepatitis" post="A vaccine in Valdivia, ChileVaccine199210 Suppl 1S152S1551335650 31RadzikowskiABanaszkiewiczAŁazowska-PrzeorekIet al.Immunogenecity"/>
  <result pre="A vaccine in Valdivia, ChileVaccine199210 Suppl 1S152S1551335650 31RadzikowskiABanaszkiewiczAŁazowska-PrzeorekIet al.Immunogenecity of" exact="hepatitis" post="A vaccine in pediatric patients with inflammatory bowel diseaseInflamm"/>
  <result pre="al.Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory" exact="bowel" post="diseaseInflamm Bowel Dis2011171117112420818674 32StarkKGüntherMNeuhausRet al.Immunogenicity and safety of hepatitis"/>
  <result pre="inflammatory bowel diseaseInflamm Bowel Dis2011171117112420818674 32StarkKGüntherMNeuhausRet al.Immunogenicity and safety of" exact="hepatitis" post="A vaccine in liver and renal transplant recipientsJ Infect"/>
  <result pre="and renal transplant recipientsJ Infect Dis19991802014201710558960 33ArslanMWiesnerRHPoteruchaJJZeinNNSafety and efficacy of" exact="hepatitis" post="A vaccination in liver transplantation recipientsTransplantation20017227227611477352 34ParkSHYangSKParkSKet al.Efficacy of"/>
  <result pre="hepatitis A vaccination in liver transplantation recipientsTransplantation20017227227611477352 34ParkSHYangSKParkSKet al.Efficacy of" exact="hepatitis" post="A vaccination and factors impacting on seroconversion in patients"/>
  <result pre="vaccination and factors impacting on seroconversion in patients with inflammatory" exact="bowel" post="diseaseInflamm Bowel Dis201420697424284413 35YoonELSinnDHLeeHWKimJHCurrent status and strategies for the"/>
  <result pre="Bowel Dis201420697424284413 35YoonELSinnDHLeeHWKimJHCurrent status and strategies for the control of" exact="viral hepatitis" post="A in KoreaClin Mol Hepatol20172319620428942621 36OttJJStevensGAGroegerJWiersmaSTGlobal epidemiology of hepatitis"/>
  <result pre="Dis201420697424284413 35YoonELSinnDHLeeHWKimJHCurrent status and strategies for the control of viral" exact="hepatitis" post="A in KoreaClin Mol Hepatol20172319620428942621 36OttJJStevensGAGroegerJWiersmaSTGlobal epidemiology of hepatitis"/>
  <result pre="viral hepatitis A in KoreaClin Mol Hepatol20172319620428942621 36OttJJStevensGAGroegerJWiersmaSTGlobal epidemiology of" exact="hepatitis" post="B virus infection: new estimates of age-specific HBsAg seroprevalence"/>
  <result pre="age-specific HBsAg seroprevalence and endemicityVaccine2012302212221922273662 37SchweitzerAHornJMikolajczykRTKrauseGOttJJEstimations of worldwide prevalence of" exact="chronic hepatitis" post="B virus infection: a systematic review of data published"/>
  <result pre="HBsAg seroprevalence and endemicityVaccine2012302212221922273662 37SchweitzerAHornJMikolajczykRTKrauseGOttJJEstimations of worldwide prevalence of chronic" exact="hepatitis" post="B virus infection: a systematic review of data published"/>
  <result pre="of data published between 1965 and 2013Lancet20153861546155526231459 38ZhangQQiWWangXet al.Epidemiology of" exact="hepatitis" post="B and hepatitis C infections and benefits of programs"/>
  <result pre="between 1965 and 2013Lancet20153861546155526231459 38ZhangQQiWWangXet al.Epidemiology of hepatitis B and" exact="hepatitis" post="C infections and benefits of programs for hepatitis prevention"/>
  <result pre="and 2013Lancet20153861546155526231459 38ZhangQQiWWangXet al.Epidemiology of hepatitis B and hepatitis C" exact="infections" post="and benefits of programs for hepatitis prevention in northeastern"/>
  <result pre="B and hepatitis C infections and benefits of programs for" exact="hepatitis" post="prevention in northeastern China: a cross-sectional studyClin Infect Dis20166230531226433720"/>
  <result pre="China: a cross-sectional studyClin Infect Dis20166230531226433720 39ParkNHChungYHLeeHSImpacts of vaccination on" exact="hepatitis" post="B viral infections in Korea over a 25-year periodIntervirology201053202820068337"/>
  <result pre="cross-sectional studyClin Infect Dis20166230531226433720 39ParkNHChungYHLeeHSImpacts of vaccination on hepatitis B" exact="viral" post="infections in Korea over a 25-year periodIntervirology201053202820068337 40collab: Korea"/>
  <result pre="studyClin Infect Dis20166230531226433720 39ParkNHChungYHLeeHSImpacts of vaccination on hepatitis B viral" exact="infections" post="in Korea over a 25-year periodIntervirology201053202820068337 40collab: Korea Centers"/>
  <result pre="in Korea over a 25-year periodIntervirology201053202820068337 40collab: Korea Centers for" exact="Disease" post="Control (KCDC)Korean National Health and Nutrition Examination Survey (KNHANES)KCDC"/>
  <result pre="Web site. http://knhanes.cdc.go.kr. Accessed Dec 31, 2019 41YeoSJLeeHSJangBIet al.Nonimmunity against" exact="hepatitis" post="B virus infection in patients newly diagnosed with inflammatory"/>
  <result pre="http://knhanes.cdc.go.kr. Accessed Dec 31, 2019 41YeoSJLeeHSJangBIet al.Nonimmunity against hepatitis B" exact="virus infection" post="in patients newly diagnosed with inflammatory bowel diseaseIntest Res20181640040830090039"/>
  <result pre="Accessed Dec 31, 2019 41YeoSJLeeHSJangBIet al.Nonimmunity against hepatitis B virus" exact="infection" post="in patients newly diagnosed with inflammatory bowel diseaseIntest Res20181640040830090039"/>
  <result pre="hepatitis B virus infection in patients newly diagnosed with inflammatory" exact="bowel" post="diseaseIntest Res20181640040830090039 42collab: European Association for the Study of"/>
  <result pre="the Study of the LiverEASL clinical practice guidelines: management of" exact="chronic hepatitis" post="B virus infectionJ Hepatol20125716718522436845 43SarinSKKumarMLauGKet al.Asian-Pacific clinical practice guidelines"/>
  <result pre="Study of the LiverEASL clinical practice guidelines: management of chronic" exact="hepatitis" post="B virus infectionJ Hepatol20125716718522436845 43SarinSKKumarMLauGKet al.Asian-Pacific clinical practice guidelines"/>
  <result pre="Hepatol20125716718522436845 43SarinSKKumarMLauGKet al.Asian-Pacific clinical practice guidelines on the management of" exact="hepatitis" post="B: a 2015 updateHepatol Int201610198 44LokASMcMahonBJChronic hepatitis BHepatology20074550753917256718 45LorasCGisbertJPMínguezMet"/>
  <result pre="the management of hepatitis B: a 2015 updateHepatol Int201610198 44LokASMcMahonBJChronic" exact="hepatitis" post="BHepatology20074550753917256718 45LorasCGisbertJPMínguezMet al.Liver dysfunction related to hepatitis B and"/>
  <result pre="updateHepatol Int201610198 44LokASMcMahonBJChronic hepatitis BHepatology20074550753917256718 45LorasCGisbertJPMínguezMet al.Liver dysfunction related to" exact="hepatitis" post="B and C in patients with inflammatory bowel disease"/>
  <result pre="dysfunction related to hepatitis B and C in patients with" exact="inflammatory bowel disease" post="treated with immunosuppressive therapyGut2010591340134620577000 46LeeYHBaeSCSongGGHepatitis B virus (HBV) reactivation"/>
  <result pre="related to hepatitis B and C in patients with inflammatory" exact="bowel" post="disease treated with immunosuppressive therapyGut2010591340134620577000 46LeeYHBaeSCSongGGHepatitis B virus (HBV)"/>
  <result pre="to hepatitis B and C in patients with inflammatory bowel" exact="disease" post="treated with immunosuppressive therapyGut2010591340134620577000 46LeeYHBaeSCSongGGHepatitis B virus (HBV) reactivation"/>
  <result pre="treated with immunosuppressive therapyGut2010591340134620577000 46LeeYHBaeSCSongGGHepatitis B virus (HBV) reactivation in" exact="rheumatic" post="patients with hepatitis core antigen (HBV occult carriers) undergoing"/>
  <result pre="therapyGut2010591340134620577000 46LeeYHBaeSCSongGGHepatitis B virus (HBV) reactivation in rheumatic patients with" exact="hepatitis" post="core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor"/>
  <result pre="48HammondSPBorcheltAMUkomaduCHoVTBadenLRMartyFMHepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantationBiol" exact="Blood" post="Marrow Transplant2009151049105919660717 49KanaanNKabambaBMaréchalCet al.Significant rate of hepatitis B reactivation"/>
  <result pre="stem cell transplantationBiol Blood Marrow Transplant2009151049105919660717 49KanaanNKabambaBMaréchalCet al.Significant rate of" exact="hepatitis" post="B reactivation following kidney transplantation in patients with resolved"/>
  <result pre="after allogeneic hematopoietic stem cell transplantation in patients with previous" exact="hepatitis" post="B virus infectionTransplantation20057961661915753855 51PapaAFeliceCMarzoMet al.Prevalence and natural history of"/>
  <result pre="hepatitis B virus infectionTransplantation20057961661915753855 51PapaAFeliceCMarzoMet al.Prevalence and natural history of" exact="hepatitis" post="B and C infections in a large population of"/>
  <result pre="51PapaAFeliceCMarzoMet al.Prevalence and natural history of hepatitis B and C" exact="infections" post="in a large population of IBD patients treated with"/>
  <result pre="with anti-tumor necrosis factor-alpha agentsJ Crohns Colitis2013711311922464811 52ChevauxJBNaniAOussalahAet al.Prevalence of" exact="hepatitis" post="B and C and risk factors for nonvaccination in"/>
  <result pre="hepatitis B and C and risk factors for nonvaccination in" exact="inflammatory bowel disease" post="patients in northeast FranceInflamm Bowel Dis20101691692419885908 53LorasCSaroCGonzalez-HuixFet al.Prevalence and"/>
  <result pre="B and C and risk factors for nonvaccination in inflammatory" exact="bowel" post="disease patients in northeast FranceInflamm Bowel Dis20101691692419885908 53LorasCSaroCGonzalez-HuixFet al.Prevalence"/>
  <result pre="and C and risk factors for nonvaccination in inflammatory bowel" exact="disease" post="patients in northeast FranceInflamm Bowel Dis20101691692419885908 53LorasCSaroCGonzalez-HuixFet al.Prevalence and"/>
  <result pre="northeast FranceInflamm Bowel Dis20101691692419885908 53LorasCSaroCGonzalez-HuixFet al.Prevalence and factors related to" exact="hepatitis" post="B and C in inflammatory bowel disease patients in"/>
  <result pre="al.Prevalence and factors related to hepatitis B and C in" exact="inflammatory bowel disease" post="patients in Spain: a nationwide, multicenter studyAm J Gastroenterol2009104576319098850"/>
  <result pre="and factors related to hepatitis B and C in inflammatory" exact="bowel" post="disease patients in Spain: a nationwide, multicenter studyAm J"/>
  <result pre="factors related to hepatitis B and C in inflammatory bowel" exact="disease" post="patients in Spain: a nationwide, multicenter studyAm J Gastroenterol2009104576319098850"/>
  <result pre="Spain: a nationwide, multicenter studyAm J Gastroenterol2009104576319098850 54ZuckermanJvan HattumJCafferkeyMet al.Should" exact="hepatitis" post="B vaccination be introduced into childhood immunisation programmes in"/>
  <result pre="Gastroenterol2009104576319098850 54ZuckermanJvan HattumJCafferkeyMet al.Should hepatitis B vaccination be introduced into" exact="childhood" post="immunisation programmes in northern Europe?Lancet Infect Dis2007741041917521594 55MereckieneJCotterSLopalcoPet al.Hepatitis"/>
  <result pre="PublicationHepatitis B vaccines: WHO position paper: recommendationsVaccine20102858959019896455 57MelmedGYIppolitiAFPapadakisKAet al.Patients with" exact="inflammatory bowel disease" post="are at risk for vaccine-preventable illnessesAm J Gastroenterol20061011834184016817843 58LokASLaiCLWuPCPrevalence"/>
  <result pre="B vaccines: WHO position paper: recommendationsVaccine20102858959019896455 57MelmedGYIppolitiAFPapadakisKAet al.Patients with inflammatory" exact="bowel" post="disease are at risk for vaccine-preventable illnessesAm J Gastroenterol20061011834184016817843"/>
  <result pre="vaccines: WHO position paper: recommendationsVaccine20102858959019896455 57MelmedGYIppolitiAFPapadakisKAet al.Patients with inflammatory bowel" exact="disease" post="are at risk for vaccine-preventable illnessesAm J Gastroenterol20061011834184016817843 58LokASLaiCLWuPCPrevalence"/>
  <result pre="for vaccine-preventable illnessesAm J Gastroenterol20061011834184016817843 58LokASLaiCLWuPCPrevalence of isolated antibody to" exact="hepatitis" post="B core antigen in an area endemic for hepatitis"/>
  <result pre="to hepatitis B core antigen in an area endemic for" exact="hepatitis" post="B virus infection: implications in hepatitis B vaccination programsHepatology198887667702968945"/>
  <result pre="an area endemic for hepatitis B virus infection: implications in" exact="hepatitis" post="B vaccination programsHepatology198887667702968945 59McMahonBJParkinsonAJHelminiakCet al.Response to hepatitis B vaccine"/>
  <result pre="infection: implications in hepatitis B vaccination programsHepatology198887667702968945 59McMahonBJParkinsonAJHelminiakCet al.Response to" exact="hepatitis" post="B vaccine of persons positive for antibody to hepatitis"/>
  <result pre="to hepatitis B vaccine of persons positive for antibody to" exact="hepatitis" post="B core antigenGastroenterology19921035905941386048 60JiangHYWangSYDengMet al.Immune response to hepatitis B"/>
  <result pre="antibody to hepatitis B core antigenGastroenterology19921035905941386048 60JiangHYWangSYDengMet al.Immune response to" exact="hepatitis" post="B vaccination among people with inflammatory bowel diseases: a"/>
  <result pre="al.Immune response to hepatitis B vaccination among people with inflammatory" exact="bowel" post="diseases: a systematic review and meta-analysisVaccine2017352633264128404358 61CoatesTWilsonRPatrickGAndréFWatsonVHepatitis B vaccines:"/>
  <result pre="Ther20012339240311318074 62Vida PérezLGómez CamachoFGarcía SánchezVet al.Adequate rate of response to" exact="hepatitis" post="B virus vaccination in patients with inflammatory bowel diseaseMed"/>
  <result pre="response to hepatitis B virus vaccination in patients with inflammatory" exact="bowel" post="diseaseMed Clin (Barc)200913233133519268981 63AltunözMESenateşEYeşilACalhanTOvünçAOPatients with inflammatory bowel disease have"/>
  <result pre="in patients with inflammatory bowel diseaseMed Clin (Barc)200913233133519268981 63AltunözMESenateşEYeşilACalhanTOvünçAOPatients with" exact="inflammatory bowel disease" post="have a lower response rate to HBV vaccination compared"/>
  <result pre="patients with inflammatory bowel diseaseMed Clin (Barc)200913233133519268981 63AltunözMESenateşEYeşilACalhanTOvünçAOPatients with inflammatory" exact="bowel" post="disease have a lower response rate to HBV vaccination"/>
  <result pre="with inflammatory bowel diseaseMed Clin (Barc)200913233133519268981 63AltunözMESenateşEYeşilACalhanTOvünçAOPatients with inflammatory bowel" exact="disease" post="have a lower response rate to HBV vaccination compared"/>
  <result pre="diseaseMed Clin (Barc)200913233133519268981 63AltunözMESenateşEYeşilACalhanTOvünçAOPatients with inflammatory bowel disease have a" exact="lower" post="response rate to HBV vaccination compared to controlsDig Dis"/>
  <result pre="of two protocols for vaccination (standard and double dosage) against" exact="hepatitis" post="B virus in patients with inflammatory bowel diseaseAliment Pharmacol"/>
  <result pre="double dosage) against hepatitis B virus in patients with inflammatory" exact="bowel" post="diseaseAliment Pharmacol Ther2012351379138522530631 65LamperticoPMainiMPapatheodoridisGOptimal management of hepatitis B virus"/>
  <result pre="patients with inflammatory bowel diseaseAliment Pharmacol Ther2012351379138522530631 65LamperticoPMainiMPapatheodoridisGOptimal management of" exact="hepatitis" post="B virus infection: EASL Special ConferenceJ Hepatol2015631238125326150256 66GisbertJPVillagrasaJRRodríguez-NogueirasAChaparroMEfficacy of"/>
  <result pre="hepatitis B virus infection: EASL Special ConferenceJ Hepatol2015631238125326150256 66GisbertJPVillagrasaJRRodríguez-NogueirasAChaparroMEfficacy of" exact="hepatitis" post="B vaccination and revaccination and factors impacting on response"/>
  <result pre="revaccination and factors impacting on response in patients with inflammatory" exact="bowel" post="diseaseAm J Gastroenterol20121071460146623034605 67GisbertJPChaparroMVaccination strategies in patients with IBDNat"/>
  <result pre="on the humoral response to influenza vaccination in patients with" exact="rheumatoid arthritis" post="and ankylosing spondylitisSemin Arthritis Rheum20103944244719246078 69AgarwalNOllingtonKKaneshiroMFrenckRMelmedGYAre immunosuppressive medications associated"/>
  <result pre="the humoral response to influenza vaccination in patients with rheumatoid" exact="arthritis" post="and ankylosing spondylitisSemin Arthritis Rheum20103944244719246078 69AgarwalNOllingtonKKaneshiroMFrenckRMelmedGYAre immunosuppressive medications associated"/>
  <result pre="influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitisSemin" exact="Arthritis" post="Rheum20103944244719246078 69AgarwalNOllingtonKKaneshiroMFrenckRMelmedGYAre immunosuppressive medications associated with decreased responses to"/>
  <result pre="resultsGut201564778324763133 71MastEEWeinbaumCMFioreAEet al.A comprehensive immunization strategy to eliminate transmission of" exact="hepatitis" post="B virus infection in the United States: recommendations of"/>
  <result pre="al.A comprehensive immunization strategy to eliminate transmission of hepatitis B" exact="virus infection" post="in the United States: recommendations of the Advisory Committee"/>
  <result pre="comprehensive immunization strategy to eliminate transmission of hepatitis B virus" exact="infection" post="in the United States: recommendations of the Advisory Committee"/>
  <result pre="immunization of adultsMMWR Recomm Rep200655RR-16133 72collab: European Consensus Group on" exact="Hepatitis" post="B ImmunityAre booster immunisations needed for lifelong hepatitis B"/>
  <result pre="Group on Hepatitis B ImmunityAre booster immunisations needed for lifelong" exact="hepatitis" post="B immunity?Lancet200035556156510683019 73collab: Korean Society of Infectious DiseasesVaccination for"/>
  <result pre="needed for lifelong hepatitis B immunity?Lancet200035556156510683019 73collab: Korean Society of" exact="Infectious" post="DiseasesVaccination for adult2nd edSeoulM.I.P.2012 74GisbertJPVillagrasaJRRodríguez-NogueirasAChaparroMKinetics of anti-hepatitis B surface"/>
  <result pre="adult2nd edSeoulM.I.P.2012 74GisbertJPVillagrasaJRRodríguez-NogueirasAChaparroMKinetics of anti-hepatitis B surface antigen titers after" exact="hepatitis" post="B vaccination in patients with inflammatory bowel diseaseInflamm Bowel"/>
  <result pre="antigen titers after hepatitis B vaccination in patients with inflammatory" exact="bowel" post="diseaseInflamm Bowel Dis20131955455823380936 75VisserLGTNF-alpha antagonists and immunizationCurr Infect Dis"/>
  <result pre="B immunity and response to booster vaccination in children with" exact="inflammatory bowel disease" post="treated with infliximabAm J Gastroenterol201210713313821876562 78Lao-ArayaMPuthanakitTAurpibulLTaecharoenkulSSirisanthanaTSirisanthanaVPrevalence of protective level"/>
  <result pre="immunity and response to booster vaccination in children with inflammatory" exact="bowel" post="disease treated with infliximabAm J Gastroenterol201210713313821876562 78Lao-ArayaMPuthanakitTAurpibulLTaecharoenkulSSirisanthanaTSirisanthanaVPrevalence of protective"/>
  <result pre="and response to booster vaccination in children with inflammatory bowel" exact="disease" post="treated with infliximabAm J Gastroenterol201210713313821876562 78Lao-ArayaMPuthanakitTAurpibulLTaecharoenkulSSirisanthanaTSirisanthanaVPrevalence of protective level"/>
  <result pre="treated with infliximabAm J Gastroenterol201210713313821876562 78Lao-ArayaMPuthanakitTAurpibulLTaecharoenkulSSirisanthanaTSirisanthanaVPrevalence of protective level of" exact="hepatitis" post="B antibody 3 years after revaccination in HIV-infected children"/>
  <result pre="lifelong? Milan, Italy, 17-18 November 2011Vaccine20133158459023142301 80LokASMcMahonBJcollab: Practice Guidelines Committeecollab:" exact="American" post="Association for the Study of Liver Diseases (AASLD)Chronic hepatitis"/>
  <result pre="80LokASMcMahonBJcollab: Practice Guidelines Committeecollab: American Association for the Study of" exact="Liver Diseases" post="(AASLD)Chronic hepatitis B: update of recommendationsHepatology20043985786114999707 81HwangJPLokASManagement of patients"/>
  <result pre="Practice Guidelines Committeecollab: American Association for the Study of Liver" exact="Diseases" post="(AASLD)Chronic hepatitis B: update of recommendationsHepatology20043985786114999707 81HwangJPLokASManagement of patients"/>
  <result pre="Committeecollab: American Association for the Study of Liver Diseases (AASLD)Chronic" exact="hepatitis" post="B: update of recommendationsHepatology20043985786114999707 81HwangJPLokASManagement of patients with hepatitis"/>
  <result pre="(AASLD)Chronic hepatitis B: update of recommendationsHepatology20043985786114999707 81HwangJPLokASManagement of patients with" exact="hepatitis" post="B who require immunosuppressive therapyNat Rev Gastroenterol Hepatol20141120921924247262 82BessoneFDirchwolfMManagement"/>
  <result pre="B who require immunosuppressive therapyNat Rev Gastroenterol Hepatol20141120921924247262 82BessoneFDirchwolfMManagement of" exact="hepatitis" post="B reactivation in immunosuppressed patients: an update on current"/>
  <result pre="directionsGastroenterology20171521297130928219691 84LoombaRRowleyAWesleyRet al.Systematic review: the effect of preventive lamivudine on" exact="hepatitis" post="B reactivation during chemotherapyAnn Intern Med200814851952818378948 85YeoWChanPKZhongSet al.Frequency of"/>
  <result pre="hepatitis B reactivation during chemotherapyAnn Intern Med200814851952818378948 85YeoWChanPKZhongSet al.Frequency of" exact="hepatitis" post="B virus reactivation in cancer patients undergoing cytotoxic chemotherapy:"/>
  <result pre="Intern Med200814851952818378948 85YeoWChanPKZhongSet al.Frequency of hepatitis B virus reactivation in" exact="cancer" post="patients undergoing cytotoxic chemotherapy: a prospective study of 626"/>
  <result pre="risk factorsJ Med Virol20006229930711055239 86YeoWChanPKHoWMet al.Lamivudine for the prevention of" exact="hepatitis" post="B virus reactivation in hepatitis B s-antigen seropositive cancer"/>
  <result pre="al.Lamivudine for the prevention of hepatitis B virus reactivation in" exact="hepatitis" post="B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapyJ Clin"/>
  <result pre="of hepatitis B virus reactivation in hepatitis B s-antigen seropositive" exact="cancer" post="patients undergoing cytotoxic chemotherapyJ Clin Oncol20042292793414990649 87YeoWChanPKHuiPet al.Hepatitis B"/>
  <result pre="cytotoxic chemotherapyJ Clin Oncol20042292793414990649 87YeoWChanPKHuiPet al.Hepatitis B virus reactivation in" exact="breast cancer" post="patients receiving cytotoxic chemotherapy: a prospective studyJ Med Virol20037055356112794717"/>
  <result pre="chemotherapyJ Clin Oncol20042292793414990649 87YeoWChanPKHuiPet al.Hepatitis B virus reactivation in breast" exact="cancer" post="patients receiving cytotoxic chemotherapy: a prospective studyJ Med Virol20037055356112794717"/>
  <result pre="a prospective studyJ Med Virol20037055356112794717 88YeoWJohnsonPJDiagnosis, prevention and management of" exact="hepatitis" post="B virus reactivation during anticancer therapyHepatology20064320922016440366 89TohmeRABulkowLHomanCENegusSMcMahonBJRates and risk"/>
  <result pre="virus reactivation during anticancer therapyHepatology20064320922016440366 89TohmeRABulkowLHomanCENegusSMcMahonBJRates and risk factors for" exact="hepatitis" post="B reactivation in a cohort of persons in the"/>
  <result pre="in a cohort of persons in the inactive phase of" exact="chronic hepatitis" post="B: Alaska, 2001-2010J Clin Virol20135839640024001884 90BorentainPColsonPCosoDet al.Clinical and virological"/>
  <result pre="a cohort of persons in the inactive phase of chronic" exact="hepatitis" post="B: Alaska, 2001-2010J Clin Virol20135839640024001884 90BorentainPColsonPCosoDet al.Clinical and virological"/>
  <result pre="2001-2010J Clin Virol20135839640024001884 90BorentainPColsonPCosoDet al.Clinical and virological factors associated with" exact="hepatitis" post="B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients"/>
  <result pre="patients undergoing chemotherapy and/or autologous stem cell transplantation for cancerJ" exact="Viral" post="Hepat20101780781520002298 91HayashiKIshigamiMIshizuYet al.Clinical characteristics and molecular analysis of hepatitis"/>
  <result pre="cancerJ Viral Hepat20101780781520002298 91HayashiKIshigamiMIshizuYet al.Clinical characteristics and molecular analysis of" exact="hepatitis" post="B virus reactivation in hepatitis B surface antigen-negative patients"/>
  <result pre="characteristics and molecular analysis of hepatitis B virus reactivation in" exact="hepatitis" post="B surface antigen-negative patients during or after immunosuppressive or"/>
  <result pre="cytotoxic chemotherapyJ Gastroenterol2016511081108926943169 92XuZDaiWWuYTet al.Prophylactic effect of lamivudine on chemotherapy-induced" exact="hepatitis" post="B virus reactivation in patients with solid tumour: a"/>
  <result pre="virus reactivation in patients with solid tumour: a meta-analysisEur J" exact="Cancer" post="Care (Engl)201827e1279929265535 93El-SayedMHMohamedMMKarimAet al.Severe liver disease is caused by"/>
  <result pre="solid tumour: a meta-analysisEur J Cancer Care (Engl)201827e1279929265535 93El-SayedMHMohamedMMKarimAet al.Severe" exact="liver disease" post="is caused by HBV rather than HCV in children"/>
  <result pre="tumour: a meta-analysisEur J Cancer Care (Engl)201827e1279929265535 93El-SayedMHMohamedMMKarimAet al.Severe liver" exact="disease" post="is caused by HBV rather than HCV in children"/>
  <result pre="than HCV in children with hematological malignanciesHematol J2003432132714502256 94ChungSJKimJKParkMCParkYBLeeSKReactivation of" exact="hepatitis" post="B viral infection in inactive HBsAg carriers following anti-tumor"/>
  <result pre="in children with hematological malignanciesHematol J2003432132714502256 94ChungSJKimJKParkMCParkYBLeeSKReactivation of hepatitis B" exact="viral infection" post="in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapyJ"/>
  <result pre="children with hematological malignanciesHematol J2003432132714502256 94ChungSJKimJKParkMCParkYBLeeSKReactivation of hepatitis B viral" exact="infection" post="in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapyJ"/>
  <result pre="inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapyJ Rheumatol2009362416242019797507 95EsteveMSaroCGonzález-HuixFSuarezFFornéMViverJMChronic" exact="hepatitis" post="B reactivation following infliximab therapy in Crohn’s disease patients:"/>
  <result pre="Rheumatol2009362416242019797507 95EsteveMSaroCGonzález-HuixFSuarezFFornéMViverJMChronic hepatitis B reactivation following infliximab therapy in Crohn’s" exact="disease" post="patients: need for primary prophylaxisGut2004531363136515306601 96KimYJBaeSCSungYKet al.Possible reactivation of"/>
  <result pre="reactivation following infliximab therapy in Crohn’s disease patients: need for" exact="primary" post="prophylaxisGut2004531363136515306601 96KimYJBaeSCSungYKet al.Possible reactivation of potential hepatitis B virus"/>
  <result pre="patients: need for primary prophylaxisGut2004531363136515306601 96KimYJBaeSCSungYKet al.Possible reactivation of potential" exact="hepatitis" post="B virus occult infection by tumor necrosis factor-alpha blocker"/>
  <result pre="prophylaxisGut2004531363136515306601 96KimYJBaeSCSungYKet al.Possible reactivation of potential hepatitis B virus occult" exact="infection" post="by tumor necrosis factor-alpha blocker in the treatment of"/>
  <result pre="al.Possible reactivation of potential hepatitis B virus occult infection by" exact="tumor" post="necrosis factor-alpha blocker in the treatment of rheumatic diseasesJ"/>
  <result pre="infection by tumor necrosis factor-alpha blocker in the treatment of" exact="rheumatic" post="diseasesJ Rheumatol20103734635020008922 97ParkSHYangSKLimYSet al.Clinical courses of chronic hepatitis B"/>
  <result pre="the treatment of rheumatic diseasesJ Rheumatol20103734635020008922 97ParkSHYangSKLimYSet al.Clinical courses of" exact="chronic hepatitis" post="B virus infection and inflammatory bowel disease in patients"/>
  <result pre="treatment of rheumatic diseasesJ Rheumatol20103734635020008922 97ParkSHYangSKLimYSet al.Clinical courses of chronic" exact="hepatitis" post="B virus infection and inflammatory bowel disease in patients"/>
  <result pre="rheumatic diseasesJ Rheumatol20103734635020008922 97ParkSHYangSKLimYSet al.Clinical courses of chronic hepatitis B" exact="virus infection" post="and inflammatory bowel disease in patients with both diseasesInflamm"/>
  <result pre="diseasesJ Rheumatol20103734635020008922 97ParkSHYangSKLimYSet al.Clinical courses of chronic hepatitis B virus" exact="infection" post="and inflammatory bowel disease in patients with both diseasesInflamm"/>
  <result pre="97ParkSHYangSKLimYSet al.Clinical courses of chronic hepatitis B virus infection and" exact="inflammatory bowel disease" post="in patients with both diseasesInflamm Bowel Dis2012182004201022337144 98PerrilloRPGishRFalck-YtterYTAmerican Gastroenterological"/>
  <result pre="al.Clinical courses of chronic hepatitis B virus infection and inflammatory" exact="bowel" post="disease in patients with both diseasesInflamm Bowel Dis2012182004201022337144 98PerrilloRPGishRFalck-YtterYTAmerican"/>
  <result pre="courses of chronic hepatitis B virus infection and inflammatory bowel" exact="disease" post="in patients with both diseasesInflamm Bowel Dis2012182004201022337144 98PerrilloRPGishRFalck-YtterYTAmerican Gastroenterological"/>
  <result pre="Gastroenterological Association Institute technical review on prevention and treatment of" exact="hepatitis" post="B virus reactivation during immunosuppressive drug therapyGastroenterology201514822124425447852 99ReddyKRBeaversKLHammondSPLimJKFalck-Ytter YT;"/>
  <result pre="hepatitis B virus reactivation during immunosuppressive drug therapyGastroenterology201514822124425447852 99ReddyKRBeaversKLHammondSPLimJKFalck-Ytter YT;" exact="American" post="Gastroenterological AssociationInstituteAmerican Gastroenterological Association Institute guideline on the prevention"/>
  <result pre="Gastroenterological Association Institute guideline on the prevention and treatment of" exact="hepatitis" post="B virus reactivation during immunosuppressive drug therapyGastroenterology201514821521925447850 100CalabreseLHZeinNNVassilopoulosDHepatitis B"/>
  <result pre="therapyGastroenterology201514821521925447850 100CalabreseLHZeinNNVassilopoulosDHepatitis B virus (HBV) reactivation with immunosuppressive therapy in" exact="rheumatic" post="diseases: assessment and preventive strategiesAnn Rheum Dis20066598398916627542 101LanJLChenYMHsiehTYet al.Kinetics"/>
  <result pre="diseases: assessment and preventive strategiesAnn Rheum Dis20066598398916627542 101LanJLChenYMHsiehTYet al.Kinetics of" exact="viral" post="loads and risk of hepatitis B virus reactivation in"/>
  <result pre="Rheum Dis20066598398916627542 101LanJLChenYMHsiehTYet al.Kinetics of viral loads and risk of" exact="hepatitis" post="B virus reactivation in hepatitis B core antibody-positive rheumatoid"/>
  <result pre="viral loads and risk of hepatitis B virus reactivation in" exact="hepatitis" post="B core antibody-positive rheumatoid arthritis patients undergoing antitumour necrosis"/>
  <result pre="of hepatitis B virus reactivation in hepatitis B core antibody-positive" exact="rheumatoid arthritis" post="patients undergoing antitumour necrosis factor alpha therapyAnn Rheum Dis2011701719172521719446"/>
  <result pre="hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid" exact="arthritis" post="patients undergoing antitumour necrosis factor alpha therapyAnn Rheum Dis2011701719172521719446"/>
  <result pre="therapyAnn Rheum Dis2011701719172521719446 102LuciforaJXiaYReisingerFet al.Specific and nonhepatotoxic degradation of nuclear" exact="hepatitis" post="B virus cccDNAScience20143431221122824557838 103KoskinasJTampakiMDoumbaPPRallisEHepatitis B virus reactivation during therapy"/>
  <result pre="cccDNAScience20143431221122824557838 103KoskinasJTampakiMDoumbaPPRallisEHepatitis B virus reactivation during therapy with ustekinumab for" exact="psoriasis" post="in a hepatitis B surface-antigen-negative anti-HBs-positive patientBr J Dermatol201316867968023121260"/>
  <result pre="virus reactivation during therapy with ustekinumab for psoriasis in a" exact="hepatitis" post="B surface-antigen-negative anti-HBs-positive patientBr J Dermatol201316867968023121260 104NakanoNKusumotoSTanakaYet al.Reactivation of"/>
  <result pre="hepatitis B surface-antigen-negative anti-HBs-positive patientBr J Dermatol201316867968023121260 104NakanoNKusumotoSTanakaYet al.Reactivation of" exact="hepatitis" post="B virus in a patient with adult T-cell leukemia-lymphoma"/>
  <result pre="104NakanoNKusumotoSTanakaYet al.Reactivation of hepatitis B virus in a patient with" exact="adult" post="T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody"/>
  <result pre="reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysisJ" exact="Viral" post="Hepat20152284284925765930 107ZhangMYZhuGQShiKQet al.Systematic review with network meta-analysis: comparative efficacy"/>
  <result pre="of oral nucleos(t) ide analogues for the prevention of chemotherapy-induced" exact="hepatitis" post="B virus reactivationOncotarget20167306423065827121321 108YangCQinBYuanZChenLZhouHYMeta-analysis of prophylactic entecavir or lamivudine"/>
  <result pre="B virus reactivationOncotarget20167306423065827121321 108YangCQinBYuanZChenLZhouHYMeta-analysis of prophylactic entecavir or lamivudine against" exact="hepatitis" post="B virus reactivationAnn Hepatol20161550151127236149 109YuSLuoHPanMet al.Comparison of entecavir and"/>
  <result pre="al.Comparison of entecavir and lamivudine in preventing HBV reactivation in" exact="lymphoma" post="patients undergoing chemotherapy: a meta-analysisInt J Clin Pharm2016381035104327450506 110CervaCColagrossiLMaffongelliGet"/>
  <result pre="reactivation after withdrawal of prophylactic antiviral therapy in patients with" exact="diffuse" post="large B cell lymphomaLeuk Lymphoma2016571355136226727044 112NakayaAFujitaSSatakeAet al.Delayed HBV reactivation"/>
  <result pre="we continue anti-virus prophylaxis or monitoring HBV-DNA?Leuk Res201650464927665181 113ViganòMSerraGCasellaGGrossiGLamperticoPReactivation of" exact="hepatitis" post="B virus during targeted therapies for cancer and immune-mediated"/>
  <result pre="Res201650464927665181 113ViganòMSerraGCasellaGGrossiGLamperticoPReactivation of hepatitis B virus during targeted therapies for" exact="cancer" post="and immune-mediated disordersExpert Opin Biol Ther20161691792627088278 114CholongitasETziomalosKPipiliCManagement of patients"/>
  <result pre="and immune-mediated disordersExpert Opin Biol Ther20161691792627088278 114CholongitasETziomalosKPipiliCManagement of patients with" exact="hepatitis" post="B in special populationsWorld J Gastroenterol2015211738174825684938 115PattulloVPrevention of hepatitis"/>
  <result pre="with hepatitis B in special populationsWorld J Gastroenterol2015211738174825684938 115PattulloVPrevention of" exact="hepatitis" post="B reactivation in the setting of immunosuppressionClin Mol Hepatol20162221923727291888"/>
  <result pre="B reactivation in the setting of immunosuppressionClin Mol Hepatol20162221923727291888 116PhippsCChenYTanDLymphoproliferative" exact="disease" post="and hepatitis B reactivation: challenges in the era of"/>
  <result pre="in the setting of immunosuppressionClin Mol Hepatol20162221923727291888 116PhippsCChenYTanDLymphoproliferative disease and" exact="hepatitis" post="B reactivation: challenges in the era of rapidly evolving"/>
  <result pre="reactivation: challenges in the era of rapidly evolving targeted therapyClin" exact="Lymphoma" post="Myeloma Leuk20161651126705677 117VoicanCSMirOLoulerguePet al.Hepatitis B virus reactivation in patients"/>
  <result pre="challenges in the era of rapidly evolving targeted therapyClin Lymphoma" exact="Myeloma" post="Leuk20161651126705677 117VoicanCSMirOLoulerguePet al.Hepatitis B virus reactivation in patients with"/>
  <result pre="al.Hepatitis B virus reactivation in patients with solid tumors receiving" exact="systemic" post="anticancer treatmentAnn Oncol2016272172218427803003 118MadoniaSOrlandoAScimecaDOlivoMRossiFCottoneMOccult hepatitis B and infliximab-induced HBV"/>
  <result pre="patients with solid tumors receiving systemic anticancer treatmentAnn Oncol2016272172218427803003 118MadoniaSOrlandoAScimecaDOlivoMRossiFCottoneMOccult" exact="hepatitis" post="B and infliximab-induced HBV reactivationInflamm Bowel Dis20071350850917206687 119PetruzzielloAMariglianoSLoquercioGCozzolinoACacciapuotiCGlobal epidemiology"/>
  <result pre="B and infliximab-induced HBV reactivationInflamm Bowel Dis20071350850917206687 119PetruzzielloAMariglianoSLoquercioGCozzolinoACacciapuotiCGlobal epidemiology of" exact="hepatitis" post="C virus infection: an up-date of the distribution and"/>
  <result pre="virus infection: an up-date of the distribution and circulation of" exact="hepatitis" post="C virus genotypesWorld J Gastroenterol2016227824784027678366 120KimYSPaiCHChiHSKimDWMinYIAhnYOPrevalence of hepatitis C"/>
  <result pre="circulation of hepatitis C virus genotypesWorld J Gastroenterol2016227824784027678366 120KimYSPaiCHChiHSKimDWMinYIAhnYOPrevalence of" exact="hepatitis" post="C virus antibody among Korean adultsJ Korean Med Sci199273333361284374"/>
  <result pre="Korean adultsJ Korean Med Sci199273333361284374 121KimDYKimIHJeongSHet al.A nationwide seroepidemiology of" exact="hepatitis" post="C virus infection in South KoreaLiver Int20133358659423356674 122collab: Korean"/>
  <result pre="Korean Med Sci199273333361284374 121KimDYKimIHJeongSHet al.A nationwide seroepidemiology of hepatitis C" exact="virus infection" post="in South KoreaLiver Int20133358659423356674 122collab: Korean Association for the"/>
  <result pre="Med Sci199273333361284374 121KimDYKimIHJeongSHet al.A nationwide seroepidemiology of hepatitis C virus" exact="infection" post="in South KoreaLiver Int20133358659423356674 122collab: Korean Association for the"/>
  <result pre="Study of the Liver (KASL)KASL clinical practice guidelines: management of" exact="hepatitis" post="CClin Mol Hepatol2014208913625032178 123HellardMSacks-DavisRDoyleJHepatitis C elimination by 2030 through"/>
  <result pre="Health2016701151115427343304 124BrunassoAMPuntoniMGuliaAMassoneCSafety of antitumour necrosis factor agents in patients with" exact="chronic hepatitis" post="C infection: a systematic reviewRheumatology (Oxford)2011501700171121690185 125PawlotskyJMMolecular diagnosis of"/>
  <result pre="124BrunassoAMPuntoniMGuliaAMassoneCSafety of antitumour necrosis factor agents in patients with chronic" exact="hepatitis" post="C infection: a systematic reviewRheumatology (Oxford)2011501700171121690185 125PawlotskyJMMolecular diagnosis of"/>
  <result pre="hepatitis C infection: a systematic reviewRheumatology (Oxford)2011501700171121690185 125PawlotskyJMMolecular diagnosis of" exact="viral" post="hepatitisGastroenterology20021221554156812016423 126VermehrenJYuMLMontoAet al.Multi-center evaluation of the Abbott RealTime HCV"/>
  <result pre="RealTime HCV assay for monitoring patients undergoing antiviral therapy for" exact="chronic hepatitis" post="CJ Clin Virol20115213313721803650 Table 1. Thirteen Guidelines Selected for"/>
  <result pre="HCV assay for monitoring patients undergoing antiviral therapy for chronic" exact="hepatitis" post="CJ Clin Virol20115213313721803650 Table 1. Thirteen Guidelines Selected for"/>
  <result pre="Farraye et al. [5] ACG clinical guideline: preventive care in" exact="inflammatory bowel disease" post="USA American Journal of Gastroenterology 2017 112/241-258 Rahier et"/>
  <result pre="et al. [5] ACG clinical guideline: preventive care in inflammatory" exact="bowel" post="disease USA American Journal of Gastroenterology 2017 112/241-258 Rahier"/>
  <result pre="al. [5] ACG clinical guideline: preventive care in inflammatory bowel" exact="disease" post="USA American Journal of Gastroenterology 2017 112/241-258 Rahier et"/>
  <result pre="ACG clinical guideline: preventive care in inflammatory bowel disease USA" exact="American" post="Journal of Gastroenterology 2017 112/241-258 Rahier et al. [2]"/>
  <result pre="evidence-based consensus on the prevention, diagnosis and management of opportunistic" exact="infections" post="in inflammatory bowel disease Europe Journal of Crohn's and"/>
  <result pre="on the prevention, diagnosis and management of opportunistic infections in" exact="inflammatory bowel disease" post="Europe Journal of Crohn's and Colitis 2014 8/443-468 European"/>
  <result pre="the prevention, diagnosis and management of opportunistic infections in inflammatory" exact="bowel" post="disease Europe Journal of Crohn's and Colitis 2014 8/443-468"/>
  <result pre="prevention, diagnosis and management of opportunistic infections in inflammatory bowel" exact="disease" post="Europe Journal of Crohn's and Colitis 2014 8/443-468 European"/>
  <result pre="infections in inflammatory bowel disease Europe Journal of Crohn's and" exact="Colitis" post="2014 8/443-468 European Association for the Study of the"/>
  <result pre="[6] EASL 2017 clinical practice guidelines on the management of" exact="hepatitis" post="B virus infection Europe Journal of Hepatology 2017 67/370-398"/>
  <result pre="2017 clinical practice guidelines on the management of hepatitis B" exact="virus infection" post="Europe Journal of Hepatology 2017 67/370-398 European Association for"/>
  <result pre="clinical practice guidelines on the management of hepatitis B virus" exact="infection" post="Europe Journal of Hepatology 2017 67/370-398 European Association for"/>
  <result pre="Study of the Liver [7] EASL recommendations on treatment of" exact="hepatitis" post="C 2018 Europe Journal of Hepatology 2018 69/461-511 Terrault"/>
  <result pre="et al. [8] Update on prevention, diagnosis, and treatment of" exact="chronic hepatitis" post="B: AASLD 2018 hepatitis B guidance USA Hepatology 2018"/>
  <result pre="al. [8] Update on prevention, diagnosis, and treatment of chronic" exact="hepatitis" post="B: AASLD 2018 hepatitis B guidance USA Hepatology 2018"/>
  <result pre="prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018" exact="hepatitis" post="B guidance USA Hepatology 2018 67/1560-1599 Korean Association for"/>
  <result pre="Liver (KASL) [9] 2017 KASL clinical practice guidelines management of" exact="hepatitis" post="C: treatment of chronic hepatitis C Korea Clin Mol"/>
  <result pre="KASL clinical practice guidelines management of hepatitis C: treatment of" exact="chronic hepatitis" post="C Korea Clin Mol Hepatol 2018 24/169-229 Korean Association"/>
  <result pre="clinical practice guidelines management of hepatitis C: treatment of chronic" exact="hepatitis" post="C Korea Clin Mol Hepatol 2018 24/169-229 Korean Association"/>
  <result pre="Liver (KASL) [10] KASL clinical practice guidelines for management of" exact="chronic hepatitis" post="B Korea Clin Mol Hepatol 2019 25/93-159 Singh et"/>
  <result pre="(KASL) [10] KASL clinical practice guidelines for management of chronic" exact="hepatitis" post="B Korea Clin Mol Hepatol 2019 25/93-159 Singh et"/>
  <result pre="Clin Mol Hepatol 2019 25/93-159 Singh et al. [11] 2015" exact="American" post="College of Rheumatology guideline for the treatment of rheumatoid"/>
  <result pre="2015 American College of Rheumatology guideline for the treatment of" exact="rheumatoid arthritis" post="USA Arthritis Care &amp;amp; Research 2016 68/1-25 Rubin et"/>
  <result pre="American College of Rheumatology guideline for the treatment of rheumatoid" exact="arthritis" post="USA Arthritis Care &amp;amp; Research 2016 68/1-25 Rubin et"/>
  <result pre="of Rheumatology guideline for the treatment of rheumatoid arthritis USA" exact="Arthritis" post="Care &amp;amp; Research 2016 68/1-25 Rubin et al. [12]"/>
  <result pre="practice guideline for vaccination of the immunocompromised host USA Clinical" exact="Infectious" post="Diseases 2014 58/309-318 Bombardier et al. [13] Canadian Rheumatology"/>
  <result pre="guideline for vaccination of the immunocompromised host USA Clinical Infectious" exact="Diseases" post="2014 58/309-318 Bombardier et al. [13] Canadian Rheumatology Association"/>
  <result pre="[13] Canadian Rheumatology Association recommendations for the pharmacological management of" exact="rheumatoid arthritis" post="with traditional and biologic disease- modifying antirheumatic drugs: part"/>
  <result pre="Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid" exact="arthritis" post="with traditional and biologic disease- modifying antirheumatic drugs: part"/>
  <result pre="van Assen et al. [14] EULAR recommendations for vaccination in" exact="adult" post="patients with autoimmune inflammatory rheumatic diseases Europe Annals of"/>
  <result pre="al. [14] EULAR recommendations for vaccination in adult patients with" exact="autoimmune" post="inflammatory rheumatic diseases Europe Annals of the Rheumatic Disease"/>
  <result pre="EULAR recommendations for vaccination in adult patients with autoimmune inflammatory" exact="rheumatic" post="diseases Europe Annals of the Rheumatic Disease 2011 70/414-422"/>
  <result pre="with autoimmune inflammatory rheumatic diseases Europe Annals of the Rheumatic" exact="Disease" post="2011 70/414-422 Bühler et al. [15] Vaccination recommendations for"/>
  <result pre="Disease 2011 70/414-422 Bühler et al. [15] Vaccination recommendations for" exact="adult" post="patients with autoimmune inflammatory rheumatic diseases Swiss Swiss Medical"/>
  <result pre="Bühler et al. [15] Vaccination recommendations for adult patients with" exact="autoimmune" post="inflammatory rheumatic diseases Swiss Swiss Medical Weekly 2015 145/W14159"/>
  <result pre="al. [15] Vaccination recommendations for adult patients with autoimmune inflammatory" exact="rheumatic" post="diseases Swiss Swiss Medical Weekly 2015 145/W14159 Cordeiro et"/>
  <result pre="2015 145/W14159 Cordeiro et al. [16] Recommendations for vaccination in" exact="adult" post="patients with systemic inflammatory rheumatic diseases from the Portuguese"/>
  <result pre="et al. [16] Recommendations for vaccination in adult patients with" exact="systemic" post="inflammatory rheumatic diseases from the Portuguese Society of Rheumatology"/>
  <result pre="[16] Recommendations for vaccination in adult patients with systemic inflammatory" exact="rheumatic" post="diseases from the Portuguese Society of Rheumatology Portugal Acta"/>
  <result pre="Society of Rheumatology Portugal Acta Reumatológica Portuguesa 2016 41/112-130 ACG," exact="American" post="College of Gastroenterology; EASL, European Association for the Study"/>
  <result pre="EASL, European Association for the Study of the Liver; AASLD," exact="American" post="Association for the Study of Liver Disease; KASL, Korean"/>
  <result pre="of the Liver; AASLD, American Association for the Study of" exact="Liver Disease;" post="KASL, Korean Association for the Study of the Liver;"/>
  <result pre="KASL, Korean Association for the Study of the Liver; IDSA," exact="Infectious" post="Disease Society of America; EULAR, European League Against Rheumatism."/>
  <result pre="Korean Association for the Study of the Liver; IDSA, Infectious" exact="Disease" post="Society of America; EULAR, European League Against Rheumatism. Table"/>
 </snippets>
</snippetsTree>
